Bayer cuts four programs amid a 'slow start' to the year Endpoints News
SCOTUS declines to take up 'skinny' label generic drug case, raising ... Endpoints News
Metaphore Biotechnologies seeks to mimic nature with $50M for ... Endpoints News
Athenex files for bankruptcy to pave way for firesale of programs ... Endpoints News
Treg biotech Dualyx lands $44M for autoimmune antibodies, 2024 ... Endpoints News
Moderna goes after Alnylam, filing counterclaims in Spikevax patent ... Endpoints News
Eisai’s Leqembi and Lilly’s donanemab could bring in $10B+ in ... Endpoints News
Colombia man's mutation may hold Alzheimer's clues for future ... Endpoints News
Verve names second PCSK9 candidate; Exscientia picks another AI ... Endpoints News
Gilead and Arcus expand partnership, adding inflammation targets Endpoints News
